Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -94.30% | -53.53% | 4.49% | 10.25% | 17.10% |
| Total Depreciation and Amortization | -38.64% | -19.32% | 2.33% | -4.35% | -10.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,245.15% | 2,667.08% | -1.27% | 4.47% | 13.85% |
| Change in Net Operating Assets | 261.14% | -69.80% | -88.63% | -269.67% | -220.51% |
| Cash from Operations | -11.38% | -27.69% | -6.06% | -11.51% | 2.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -17.69% | 15.27% | -8.58% | 16.05% | 30.56% |
| Total Debt Repaid | 22.25% | -42.94% | -19.37% | -53.64% | -48.23% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23.72% | 25.38% | -12.30% | 11.50% | 28.16% |
| Foreign Exchange rate Adjustments | 99.57% | 96.72% | -7,966.67% | -566.67% | -625.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.49% | -32.62% | -164.28% | -14.31% | 51.82% |